stockrow
Monday 9 November 2026
Export LTGO’s income statement to Excel — free account
Latigo Biotherapeutics Inc
LTGO
13.14
0.54
+4.29%
Follow LTGO
Alert me
Latigo Biotherapeutics Inc (LTGO) Return on invested capital
Latigo Biotherapeutics Inc's return on invested capital over the twelve months to 30 June 2026 was 0.00%. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| RIGL Rigel Pharmaceuticals, Inc. compare | 13.7% |
| PHAR Pharming Group N.V. Sponsored ADR compare | 10.1% |
| LTGO Latigo Biotherapeutics Inc | 0.00% |
| ANRO Alto Neuroscience, Inc. compare | 0.00% |
| GLUE Monte Rosa Therapeutics, Inc. compare | 0.00% |
| IVA Inventiva S.A. Sponsored ADR compare | 0.00% |
| SNDX Syndax Pharmaceuticals, Inc. compare | −83.4% |
| ORIC Oric Pharmaceuticals, Inc. compare | −83.8% |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)